Interaction Guide · Research summary

Can I take Vitamin E with Prasugrel?

Review Vitamin E with Prasugrel: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

The added bleeding risk from vitamin E supplements with prasugrel is uncertain. Review the exact product, dose and your bleeding history with your prescriber.

What this answer covers

Oral vitamin E supplements with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.

Supplement or preparation
Vitamin E
Medication ingredient
prasugrel

What the evidence shows

NIH guidance notes that large supplemental vitamin E doses may affect clotting and platelet function. This supports a precaution with medicines affecting bleeding, but it does not provide an exact risk estimate for this antiplatelet medicine combination or demonstrate added stomach ulceration.

Consider the prescribed treatment

Prasugrel is an antiplatelet medicine supplied in hydrochloride tablets. It can cause serious bleeding, but stopping it prematurely after stent treatment can also cause serious harm. Its platelet effect lasts longer than the active metabolite remains in blood, so a short gap between doses is not an established way to prevent supplement-related bleeding.

Review the exact product

Bring the dose in mg or IU and formulation to your pharmacist. There is no validated vitamin E cutoff that guarantees safety with this drug. The high-dose supplement concern does not imply that vitamin E in ordinary foods must be avoided.

Know when to get help

Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.

Evidence and practical considerations

Side effects & toxicity

An increased bleeding rate specifically from vitamin E supplements with prasugrel has not been established.

Exact scope
Oral vitamin E supplements with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.
Medication form and route
Oral

What remains uncertain

  • Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral prasugrel hydrochloride tablets users; short human pharmacology studies where described.

Serious bleeding risk; premature discontinuation may increase stent thrombosis, MI or death. Rifampin did not change active-metabolite exposure; label expects no important CYP-induction effect.

How this applies: Exact current product label. Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.

Exact salt-to-IN bridge from product label; no herb-specific bleeding rate. Original rifampin study retained modest platelet differences beyond simplified label summary.

Source 2: Government nutrient guidance

ods.od.nih.gov · Source check Sep 10, 2026

Population: Supplement users.

High doses may affect platelet/clotting function and increase bleeding concerns with anticoagulant or antiplatelet medicines.

How this applies: General supplement precaution with exact NSAID platelet and GI context.

No exact oral prasugrel hydrochloride tablets trial or safe-dose cutoff; no demonstration of additive GI ulceration. Original guidance body read in captured web open.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

prasugrel is IN.

How this applies: Exact identity.

Not clinical evidence.

Research assessment: · Open full citations ↗

Side effects & toxicity

High-dose vitamin E deserves individualized review with bleeding-risk medicines.

Exact scope
Oral vitamin E supplements with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.
Medication form and route
Oral

What remains uncertain

  • Precaution based on defined supplement evidence and the individual drug label; no exact combination event rate or universal discontinuation rule.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral prasugrel hydrochloride tablets users; short human pharmacology studies where described.

Serious bleeding risk; premature discontinuation may increase stent thrombosis, MI or death. Rifampin did not change active-metabolite exposure; label expects no important CYP-induction effect.

How this applies: Exact current product label. Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.

Exact salt-to-IN bridge from product label; no herb-specific bleeding rate. Original rifampin study retained modest platelet differences beyond simplified label summary.

Source 2: Government nutrient guidance

ods.od.nih.gov · Source check Sep 10, 2026

Population: Supplement users.

High doses may affect platelet/clotting function and increase bleeding concerns with anticoagulant or antiplatelet medicines.

How this applies: General supplement precaution with exact NSAID platelet and GI context.

No exact oral prasugrel hydrochloride tablets trial or safe-dose cutoff; no demonstration of additive GI ulceration. Original guidance body read in captured web open.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Sources checked and article drafted.
Research summary published

Article revision: a30c3e97716053c3

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.